



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 15 March 2023
ACCEPTED 15 March 2023
PUBLISHED 04 April 2023

CITATION
Frontiers Production Office (2023) Erratum:
The landscape of immunotherapy
resistance in NSCLC.
Front. Oncol. 13:1187021.
doi: 10.3389/fonc.2023.1187021

COPYRIGHT
© 2023 Frontiers Production Office. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Erratum: The landscape of immunotherapy resistance in NSCLC

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

immunotherapy, resistance, checkpoint inhibitor, NSCLC, lung cancer

An erratum on

[The landscape of immunotherapy resistance in NSCLC](#)

by Frisone D, Friedlaender A, Addeo A and Tsantoulis P (2022) *Front. Oncol.* 12:817548.
doi: 10.3389/fonc.2022.817548

An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Geneva”.

The original version of this article has been updated.